JP2006518726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518726A5 JP2006518726A5 JP2006502131A JP2006502131A JP2006518726A5 JP 2006518726 A5 JP2006518726 A5 JP 2006518726A5 JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006518726 A5 JP2006518726 A5 JP 2006518726A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- methylquinolinio
- amido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0301478A FR2850970B1 (fr) | 2003-02-07 | 2003-02-07 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
| PCT/FR2004/000260 WO2004072027A2 (fr) | 2003-02-07 | 2004-02-05 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518726A JP2006518726A (ja) | 2006-08-17 |
| JP2006518726A5 true JP2006518726A5 (https=) | 2007-04-05 |
Family
ID=32731875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502131A Pending JP2006518726A (ja) | 2003-02-07 | 2004-02-05 | Ｇ四重鎖ｄｎａ構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1603898A2 (https=) |
| JP (1) | JP2006518726A (https=) |
| AU (1) | AU2004210753A1 (https=) |
| BR (1) | BRPI0407320A (https=) |
| CA (1) | CA2514105A1 (https=) |
| FR (1) | FR2850970B1 (https=) |
| MX (1) | MXPA05007648A (https=) |
| WO (1) | WO2004072027A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887873B2 (en) | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
| US8293716B2 (en) | 2005-05-26 | 2012-10-23 | Ramot At Tel Aviv University Ltd. | Method of treating cancer by modulation of mortalin |
| WO2008032324A2 (en) * | 2006-09-14 | 2008-03-20 | Ramot At Tel Aviv University Ltd. | Combination therapy for tumoral disease treatment |
| GB0706932D0 (en) * | 2007-04-10 | 2007-05-16 | Univ London Pharmacy | Ureylene derivatives |
| WO2009040819A2 (en) | 2007-09-25 | 2009-04-02 | Ramot At Tel Aviv University Ltd. | DOWN-REGULATION OF MORTALIN BY siRNA |
| CN101889210B (zh) | 2008-05-27 | 2014-12-10 | 松下电器产业株式会社 | G-quadruplex检测方法、形成G-quadruplex的DNA的检测方法以及端粒酶活性测定方法 |
| JP4510929B1 (ja) | 2009-04-09 | 2010-07-28 | パナソニック株式会社 | テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤 |
| CN108066341B (zh) * | 2016-11-10 | 2020-10-30 | 中国科学院化学研究所 | 化合物在制备抗癌药物中的用途 |
| CN108066340B (zh) * | 2016-11-10 | 2020-10-27 | 中国科学院化学研究所 | 药物组合物 |
| WO2018211148A1 (en) * | 2017-05-19 | 2018-11-22 | Universite De Bretagne Occidentale | Bisquinolium derivatives for preventing or treating ebv-related cancers |
| CN113272294A (zh) * | 2018-08-24 | 2021-08-17 | 雅典学院生物医学研究基金会 | 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK7402002A3 (en) * | 1999-11-29 | 2002-11-06 | Aventis Pharma Sa | Arylamine derivatives and their use as anti-telomerase agent |
| FR2819255B1 (fr) * | 2001-01-09 | 2003-02-28 | Aventis Pharma Sa | Derives chimiques et leur application comme agent antitelomerase |
| FR2821355A1 (fr) * | 2001-02-23 | 2002-08-30 | Aventis Pharma Sa | Derives chimiques et leur application comme agent antitelomerase |
| CO5380035A1 (es) * | 2001-03-23 | 2004-03-31 | Aventis Pharma Sa | Derivados quimicos y su aplicacion como agente antitelomerasa |
| WO2002096903A2 (fr) * | 2001-05-28 | 2002-12-05 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
-
2003
- 2003-02-07 FR FR0301478A patent/FR2850970B1/fr not_active Expired - Fee Related
-
2004
- 2004-02-05 AU AU2004210753A patent/AU2004210753A1/en not_active Abandoned
- 2004-02-05 MX MXPA05007648A patent/MXPA05007648A/es not_active Application Discontinuation
- 2004-02-05 BR BRPI0407320-7A patent/BRPI0407320A/pt not_active IP Right Cessation
- 2004-02-05 WO PCT/FR2004/000260 patent/WO2004072027A2/fr not_active Ceased
- 2004-02-05 CA CA002514105A patent/CA2514105A1/fr not_active Abandoned
- 2004-02-05 JP JP2006502131A patent/JP2006518726A/ja active Pending
- 2004-02-05 EP EP04708378A patent/EP1603898A2/fr not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI816881B (zh) | 用於治療三陰性乳癌之組合療法 | |
| EP3355926B1 (en) | Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using | |
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| US20240245694A1 (en) | Tricyclic Compounds and their Uses | |
| JP7121660B2 (ja) | 癌を処置するためのｅｚｈ２阻害剤の使用 | |
| EP3154957B1 (en) | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases | |
| KR101618037B1 (ko) | 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제 | |
| ES3011282T3 (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits | |
| ES2895749T3 (es) | Métodos de tratamiento del cáncer pancreático | |
| JP2009541223A5 (https=) | ||
| JP2020527173A5 (https=) | ||
| JP2023095928A (ja) | 癌を処置するためのｅｚｈ２阻害剤の使用 | |
| CN112585136A (zh) | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 | |
| JP2006518726A5 (https=) | ||
| Rusiecki et al. | MDM2-p53 interaction inhibitors: the current state-of-art and updated patent review (2010-present) | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| KR20220028075A (ko) | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 | |
| US9205091B2 (en) | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | |
| CA3000565C (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| TW201343169A (zh) | 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 | |
| US20240156808A1 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | |
| Shukla et al. | An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020–present): part 1-patent granted | |
| JP2008517065A (ja) | Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法 | |
| EP4069243B1 (en) | Combinations of etc-159 and olaparib for use in the treatment of pancreatic cancer, ovarian cancer and cholangio-carcinomas |